List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8815222/publications.pdf Version: 2024-02-01



INIME ROSCH

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2396-2398.e3. | 4.4 | 3 |
| 2 | Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?. Journal of Hepatology, 2022, 76, 458-463. | 3.7 | 29 |
| 3 | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology, 2022, 75, 1235-1246. | 7.3 | 45 |
| 4 | Reply. Hepatology, 2022, 76, E5-E6. | 7.3 | 0 |
| 5 | Baveno VII – Renewing consensus in portal hypertension. Journal of Hepatology, 2022, 76, 959-974. | 3.7 | 890 |
| 6 | Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis. Scientific Reports, 2022, 12, 3027. | 3.3 | 12 |
| 7 | Reply to: â€~Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'. Journal of Hepatology, 2022, 77, 567-568. | 3.7 | 2 |
| 8 | Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. Journal of Hepatology, 2022, 77, 1014-1025. | 3.7 | 64 |
| 9 | Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs, 2022, 31, 825-842. | 4.1 | 0 |
| 10 | Small diameter shunts should lead to safe expansion of the use of TIPS. Journal of Hepatology, 2021, 74, 230-234. | 3.7 | 34 |
| 11 | Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10. | 1.3 | 97 |
| 12 | Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. Journal of Hepatology, 2021, 74, 1188-1199. | 3.7 | 70 |
| 13 | Royal Free Hospitalâ€estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. Liver International, 2021, 41, 819-827. | 3.9 | 2 |
| 14 | Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. Cancers, 2021, 13, 2688. | 3.7 | 18 |
| 15 | Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target― Journal of Hepatology, 2021, 75, 248-249. | 3.7 | 0 |
| 16 | Annals for Hospitalists Inpatient Notes - Clinical Pearls—Hepatorenal Syndrome. Annals of Internal Medicine, 2021, 174, HO2-HO3. | 3.9 | 0 |
| 17 | Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. Journal of Hepatology, 2021, 75, 1367-1376. | 3.7 | 73 |
| 18 | Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. Journal of Hepatology, 2021, 75, S49-S66. | 3.7 | 146 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 19 | A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology, 2021, 74, 3146-3160. | 7.3 | 25 |
| 20 | Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350. | 3.7 | 28 |
| 21 | Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?― Journal of Hepatology, 2021, 75, 1242-1243. | 3.7 | 0 |
| 22 | Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology, 2021, 75, 589-599. | 3.7 | 36 |
| 23 | Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. Journal of Autoimmunity, 2021, 123, 102710. | 6.5 | 89 |
| 24 | Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368. | 4.9 | 3 |
| 25 | Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6. | 4.4 | 74 |
| 26 | Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895. | 3.7 | 107 |
| 27 | Beta-blockers in cirrhosis: Evidence-based indicationsÂandÂlimitations. JHEP Reports, 2020, 2, 100063. | 4.9 | 81 |
| 28 | Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats. Liver International, 2020, 40, 2500-2514. | 3.9 | 20 |
| 29 | Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. Hepatology Communications, 2020, 4, 1263-1278. | 4.3 | 57 |
| 30 | Nuclear deformation mediates liver cell mechanosensing in cirrhosis. JHEP Reports, 2020, 2, 100145. | 4.9 | 35 |
| 31 | Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. Digestive and Liver Disease, 2020, 52, 958-965. | 0.9 | 11 |
| 32 | Bacteremia and intramniotic infection due to Burkholderia cenocepacea. Clinical Microbiology and Infection, 2020, 26, 1564-1565. | 6.0 | 1 |
| 33 | Letter: improve survival! Place early preâ€emptive TIPSS in highâ€risk variceal bleeders. Alimentary Pharmacology and Therapeutics, 2020, 52, 927-928. | 3.7 | 5 |
| 34 | Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology, 2020, 73, 1415-1424. | 3.7 | 104 |
| 35 | Cirrhosis as new indication for statins. Gut, 2020, 69, 953-962. | 12.1 | 81 |
| 36 | Portal Hypertension and Cirrhosis: From Evolving Concepts to Better Therapies. Clinical Liver Disease, 2020, 15, S8-S12. | 2.1 | 7 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 37 | A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology, 2020, 72, 1353-1365. | 7.3 | 32 |
| 38 | Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091. | 3.7 | 112 |
| 39 | Preemptiveâ€TIPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293. | 7.3 | 144 |
| 40 | Emricasan (IDNâ€6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology, 2019, 69, 717-728. | 7.3 | 68 |
| 41 | The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. Journal of Hepatology, 2019, 71, 942-950. | 3.7 | 61 |
| 42 | Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respiratory Medicine,the, 2019, 7, 594-604. | 10.7 | 119 |
| 43 | A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease. Nutrients, 2019, 11, 2358. | 4.1 | 13 |
| 44 | Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. , 2019, 10, 684. | | 30 |
| 45 | New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. Cells, 2019, 8, 1062. | 4.1 | 17 |
| 46 | Muscle abnormalities in cirrhosis: Calling for more strength in evaluation and prevention. Digestive and Liver Disease, 2019, 51, 1500-1501. | 0.9 | 0 |
| 47 | Skin infection by Corynebacterium diphtheriae and Streptococcus pyogenes: an unusual association. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 678-679. | 0.5 | 0 |
| 48 | Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyteâ€Mediated Paracrine Mechanism. Hepatology Communications, 2019, 3, 987-1000. | 4.3 | 37 |
| 49 | HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials. Current Hepatology Reports, 2019, 18, 164-173. | 0.9 | 4 |
| 50 | Letter: nonselective betaâ€blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1370-1371. | 3.7 | 4 |
| 51 | Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 2101-2109.e1. | 4.4 | 24 |
| 52 | Reply. Hepatology, 2019, 70, 1079-1080. | 7.3 | 0 |
| 53 | The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology, 2019, 70, 1913-1927. | 7.3 | 226 |
| 54 | β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2019, 393, 1597-1608. | 13.7 | 375 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Balloon Tamponade and Esophageal Stenting for Esophageal Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-analysis. Seminars in Liver Disease, 2019, 39, 178-194. | 3.6 | 21 |
| 56 | Systematic review with metaâ€analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 20-30. | 3.7 | 68 |
| 57 | Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver International, 2019, 39, 705-713. | 3.9 | 17 |
| 58 | Ischemia/Reperfusion Injury in the Aged Liver: The Importance of the Sinusoidal Endothelium in Developing Therapeutic Strategies for the Elderly. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 75, 268-277. | 3.6 | 14 |
| 59 | Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. Journal of Hepatology, 2019, 70, 458-469. | 3.7 | 173 |
| 60 | Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology, 2019, 69, 1287-1299. | 7.3 | 45 |
| 61 | Editorial: use of betaâ€blockers and of band ligation in preventing first and recurrent variceal bleeding—"real life―vs evidenceâ€based decisions. Alimentary Pharmacology and Therapeutics, 2018, 47, 1222-1223. | 3.7 | 1 |
| 62 | The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatology International, 2018, 12, 1-10. | 4.2 | 81 |
| 63 | Pharmacologic prevention of variceal bleeding and rebleeding. Hepatology International, 2018, 12, 68-80. | 4.2 | 36 |
| 64 | Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology, 2018, 155, 1564-1577. | 1.3 | 97 |
| 65 | Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation, 2018, 32, e13412. | 1.6 | 9 |
| 66 | Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 1140-1153. | 1.3 | 253 |
| 67 | Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications. Biotechnology and Bioengineering, 2018, 115, 2585-2594. | 3.3 | 38 |
| 68 | Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. Hepatology Communications, 2018, 2, 933-944. | 4.3 | 21 |
| 69 | The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology, 2017, 65, 2031-2044. | 7.3 | 71 |
| 70 | Prevention and treatment of variceal haemorrhage in 2017. Liver International, 2017, 37, 104-115. | 3.9 | 57 |
| 71 | Reply. Hepatology, 2017, 65, 2121-2122. | 7.3 | 0 |
| 72 | Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. Gastroenterology, 2017, 152, 1358-1365. | 1.3 | 51 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Editorial: improving inâ€hospital management of decompensated cirrhosis by a â€~care bundle' – hope, frustration, and lessons to learn. Alimentary Pharmacology and Therapeutics, 2017, 45, 754-755. | 3.7 | 2 |
| 74 | Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension. Gut, 2017, 66, 1306-1320. | 12.1 | 14 |
| 75 | Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. Scientific Reports, 2017, 7, 3255. | 3.3 | 53 |
| 76 | Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. Shock, 2017, 47, 370-377. | 2.1 | 30 |
| 77 | Statins in cirrhosis—Ready for prime time. Hepatology, 2017, 66, 697-699. | 7.3 | 15 |
| 78 | Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient metaâ€analysis. Hepatology, 2017, 66, 1219-1231. | 7.3 | 80 |
| 79 | Mitochondriaâ€ŧargeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver International, 2017, 37, 1002-1012. | 3.9 | 42 |
| 80 | Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. Journal of Viral Hepatitis, 2017, 24, 823-831. | 2.0 | 107 |
| 81 | EUS-guided intrahepatic portosystemic shunt: A real alternative to transjugular intrahepatic portalsystemic shunt?. Gastrointestinal Endoscopy, 2017, 85, 248-249. | 1.0 | 6 |
| 82 | Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology, 2017, 65, 1293-1305. | 7.3 | 225 |
| 83 | A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Scientific Reports, 2017, 7, 10497. | 3.3 | 23 |
| 84 | Effects of All-Oral Anti-Viral Therapy on HVPG and SystemicÂHemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology, 2017, 153, 1273-1283.e1. | 1.3 | 210 |
| 85 | Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. Digestive and Liver Disease, 2017, 49, 1345-1352. | 0.9 | 48 |
| 86 | Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65, 310-335. | 7.3 | 1,520 |
| 87 | Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. Journal of Hepatology, 2017, 66, 86-94. | 3.7 | 84 |
| 88 | Reply. Hepatology, 2017, 65, 386-387. | 7.3 | 0 |
| 89 | Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology, 2016, 63, 1957-1967. | 7.3 | 174 |
| 90 | Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium. Hepatology, 2016, 63, 1368-1380. | 7.3 | 118 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Betaâ€blockers in 2016: Still the safest and most useful drugs for portal hypertension?. Hepatology, 2016, 63, 1771-1773. | 7.3 | 11 |
| 92 | Metabolomics as a diagnostic tool for idiopathic non irrhotic portal hypertension. Liver International, 2016, 36, 1051-1058. | 3.9 | 15 |
| 93 | Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016, 63, 1640-1650. | 7.3 | 73 |
| 94 | Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy. Scientific Reports, 2016, 6, 22107. | 3.3 | 35 |
| 95 | Development of hyperdynamic circulation and response to βâ€blockers in compensated cirrhosis with portal hypertension. Hepatology, 2016, 63, 197-206. | 7.3 | 143 |
| 96 | EASL International Recognition Award Recipient 2016: Prof. Roberto J. Groszmann. Journal of Hepatology, 2016, 64, 996-997. | 3.7 | 0 |
| 97 | Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs, 2016, 21, 167-181. | 2.4 | 20 |
| 98 | Reply. Hepatology, 2016, 64, 2274-2274. | 7.3 | 0 |
| 99 | Calculating Hepatic Venous Pressure Gradient: Feel Free to Stay Free. Journal of Vascular and Interventional Radiology, 2016, 27, 1138-1139. | 0.5 | 10 |
| 100 | Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate―study. Hepatology, 2016, 64, 2173-2184. | 7.3 | 251 |
| 101 | Reply. Gastroenterology, 2016, 151, 1037-1038. | 1.3 | 0 |
| 102 | Mitigating amphibian chytridiomycoses in nature. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20160207. | 4.0 | 125 |
| 103 | Editorial: increased cardiac output in cirrhosis – nonâ€invasive assessment of regional blood flow by magnetic resonance angiography. Alimentary Pharmacology and Therapeutics, 2016, 43, 1340-1342. | 3.7 | 3 |
| 104 | Esophageal varices: Stage-dependent treatment algorithm. Journal of Hepatology, 2016, 64, 746-748. | 3.7 | 23 |
| 105 | Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3. | 1.3 | 232 |
| 106 | Development of a new protocol for rapid bacterial identification and susceptibility testing directly from urine samples. Clinical Microbiology and Infection, 2016, 22, 561.e1-561.e6. | 6.0 | 49 |
| 107 | <i>Escherichia coli</i> : an old friend with new tidings. FEMS Microbiology Reviews, 2016, 40, 437-463. | 8.6 | 225 |
| 108 | Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. Journal of Hepatology, 2016, 64, 834-842. | 3.7 | 97 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. PLoS ONE, 2016, 11, e0155094. | 2.5 | 44 |
| 110 | Impact of anticoagulation on upperâ€gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015, 62, 575-583. | 7.3 | 105 |
| 111 | The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology, 2015, 62, 1584-1592. | 7.3 | 57 |
| 112 | Prognosis of acute variceal bleeding: Is being on betaâ€blockers an aggravating factor? A shortâ€term survival analysis. Hepatology, 2015, 62, 1840-1846. | 7.3 | 11 |
| 113 | Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. Radiology, 2015, 277, 268-276. | 7.3 | 26 |
| 114 | Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut, 2015, 64, 657-666. | 12.1 | 48 |
| 115 | EASL Recognition Award Recipient 2015. Journal of Hepatology, 2015, 63, 787-788. | 3.7 | 0 |
| 116 | Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. American Journal of Gastroenterology, 2015, 110, 985-992. | 0.4 | 25 |
| 117 | Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clinical Gastroenterology and Hepatology, 2015, 13, 2109-2117. | 4.4 | 64 |
| 118 | KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. Clinical Microbiology and Infection, 2015, 21, 786.e9-786.e17. | 6.0 | 60 |
| 119 | Statins and liver disease: from concern to 'wonder' drugs?. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 320-321. | 17.8 | 15 |
| 120 | Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2015, 13, 1846-1853.e1. | 4.4 | 60 |
| 121 | New cellular and molecular targets for the treatment of portal hypertension. Hepatology International, 2015, 9, 183-191. | 4.2 | 48 |
| 122 | Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. Journal of Hepatology, 2015, 62, S121-S130. | 3.7 | 189 |
| 123 | Dermatitis by Dermatophilus congolensis. Clinical Microbiology and Infection, 2015, 21, e73-e74. | 6.0 | 6 |
| 124 | Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. American Journal of Physiology - Renal Physiology, 2015, 309, G301-G309. | 3.4 | 40 |
| 125 | Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. Digestive and Liver Disease, 2015, 47, 1052-1058. | 0.9 | 22 |
| 126 | KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut, 2015, 64, 1434-1443. | 12.1 | 159 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. Journal of Hepatology, 2015, 62, 1068-1075. | 3.7 | 183 |
| 128 | ls it tea time for portal hypertension?. Clinical Science, 2014, 126, 631-632. | 4.3 | 1 |
| 129 | A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. Clinical Science, 2014, 127, 527-537. | 4.3 | 20 |
| 130 | Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver International, 2014, 34, 16-25. | 3.9 | 64 |
| 131 | An apology for beta blockers. Journal of Hepatology, 2014, 61, 450-451. | 3.7 | 6 |
| 132 | Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. Journal of Hepatology, 2014, 61, 270-277. | 3.7 | 11 |
| 133 | A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. Gastroenterology, 2014, 146, 412-419.e3. | 1.3 | 285 |
| 134 | Liver cirrhosis. Lancet, The, 2014, 383, 1749-1761. | 13.7 | 1,425 |
| 135 | Liver sinusoidal endothelial dysfunction after LPS administration: A role for inducible-nitric oxide synthase. Journal of Hepatology, 2014, 61, 1321-1327. | 3.7 | 58 |
| 136 | Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology, 2014, 60, 633-647. | 7.3 | 44 |
| 137 | Pharmacologic Management of Portal Hypertension. Clinics in Liver Disease, 2014, 18, 303-317. | 2.1 | 37 |
| 138 | Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. Journal of Hepatology, 2014, 61, 252-259. | 3.7 | 43 |
| 139 | Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. Journal of Hepatology, 2013, 58, 45-50. | 3.7 | 259 |
| 140 | Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. Hepatology, 2013, 58, 1424-1435. | 7.3 | 37 |
| 141 | The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial–stellate cell deactivation induced by statins. Journal of Hepatology, 2013, 58, 98-103. | 3.7 | 180 |
| 142 | Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. Journal of Hepatology, 2013, 58, 1140-1146. | 3.7 | 60 |
| 143 | Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. Gastroenterology, 2013, 144, 102-111.e1. | 1.3 | 437 |
| 144 | Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology, 2013, 57, 1172-1181. | 7.3 | 84 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence. Hepatology, 2013, 57, 1665-1667. | 7.3 | 10 |
| 146 | Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. Journal of Hepatology, 2013, 58, 904-910. | 3.7 | 117 |
| 147 | Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. American Journal of Physiology - Renal Physiology, 2013, 305, G496-G502. | 3.4 | 19 |
| 148 | Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. American Journal of Gastroenterology, 2013, 108, 75-82. | 0.4 | 27 |
| 149 | Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology, 2013, 58, 2079-2088. | 7.3 | 48 |
| 150 | PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. Journal of Hepatology, 2012, 56, 1033-1039. | 3.7 | 73 |
| 151 | Functional aspects on the pathophysiology of portal hypertension in cirrhosis. Journal of Hepatology, 2012, 57, 458-461. | 3.7 | 219 |
| 152 | Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Digestive and Liver Disease, 2012, 44, 855-860. | 0.9 | 113 |
| 153 | Patients Whose First Episode of Bleeding Occurs While Taking a β-Blocker Have High Long-term Risks of Rebleeding and Death. Clinical Gastroenterology and Hepatology, 2012, 10, 670-676. | 4.4 | 26 |
| 154 | Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. Hepatology, 2012, 55, 921-930. | 7.3 | 94 |
| 155 | Multiple emergences of genetically diverse amphibian-infecting chytrids include a globalized hypervirulent recombinant lineage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18732-18736. | 7.1 | 375 |
| 156 | Reply:. Hepatology, 2011, 53, 2141-2142. | 7.3 | 0 |
| 157 | Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology, 2011, 54, 555-561. | 7.3 | 240 |
| 158 | Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut, 2011, 60, 517-524. | 12.1 | 113 |
| 159 | Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. Hepatology, 2010, 51, 2108-2116. | 7.3 | 74 |
| 160 | Carvedilol for portal hypertension in patients with cirrhosis. Hepatology, 2010, 51, 2214-2218. | 7.3 | 73 |
| 161 | Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology, 2010, 52, 2044-2052. | 7.3 | 180 |
| 162 | Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. New England Journal of Medicine, 2010, 362, 2370-2379. | 27.0 | 1,075 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Prolonging Survival in Patients With Cirrhosis: Old Drugs With New Indications. Gastroenterology, 2010, 139, 1813-1815.e1. | 1.3 | 22 |
| 164 | Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. Journal of Hepatology, 2010, 52, 846-853. | 3.7 | 114 |
| 165 | Management of Varices and Variceal Hemorrhage in Cirrhosis. New England Journal of Medicine, 2010, 362, 823-832. | 27.0 | 890 |
| 166 | Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut, 2009, 58, 1144-1150. | 12.1 | 98 |
| 167 | Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology, 2009, 49, 1245-1256. | 7.3 | 272 |
| 168 | Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner is…. Hepatology, 2009, 50, 674-677. | 7.3 | 24 |
| 169 | Proteomic and phenotypic profiling of the amphibian pathogen <i>Batrachochytrium dendrobatidis</i> shows that genotype is linked to virulence. Molecular Ecology, 2009, 18, 415-429. | 3.9 | 138 |
| 170 | OP25.08: Cervical length and gestational age at admission as predictors of intra-amniotic inflammation in preterm labor with intact membranes. Ultrasound in Obstetrics and Gynecology, 2009, 34, 145-145. | 1.7 | 0 |
| 171 | Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. Journal of Hepatology, 2009, 50, 923-928. | 3.7 | 340 |
| 172 | Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. Journal of Hepatology, 2009, 51, 279-287. | 3.7 | 116 |
| 173 | Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. Gastroenterology, 2009, 136, 1651-1658. | 1.3 | 372 |
| 174 | The clinical use of HVPG measurements in chronic liver disease. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 573-582. | 17.8 | 576 |
| 175 | Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology, 2008, 47, 1248-1256. | 7.3 | 118 |
| 176 | The management of portal hypertension: Rational basis, available treatments and future options. Journal of Hepatology, 2008, 48, S68-S92. | 3.7 | 248 |
| 177 | Invasive pathogens threaten species recovery programs. Current Biology, 2008, 18, R853-R854. | 3.9 | 113 |
| 178 | Portal Hypertension and Its Complications. Gastroenterology, 2008, 134, 1715-1728. | 1.3 | 303 |
| 179 | Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. Journal of Hepatology, 2008, 48, 61-67. | 3.7 | 61 |
| 180 | Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology, 2008, 47, 1604-1614. | 7.3 | 266 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Vascular Deterioration in Cirrhosis. Journal of Clinical Gastroenterology, 2007, 41, S247-S253. | 2.2 | 126 |
| 182 | Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. Journal of Hepatology, 2007, 46, 1040-1046. | 3.7 | 203 |
| 183 | Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. Journal of Hepatology, 2007, 47, 220-227. | 3.7 | 100 |
| 184 | Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. Gastroenterology, 2007, 133, 481-488. | 1.3 | 926 |
| 185 | Evidence Against a Role for NADPH Oxidase Modulating Hepatic Vascular Tone in Cirrhosis. Gastroenterology, 2007, 133, 959-966. | 1.3 | 37 |
| 186 | How to Prevent Varices From Bleeding: Shades of Grey—The Case for Nonselective β Blockers. Gastroenterology, 2007, 133, 2029-2036. | 1.3 | 78 |
| 187 | Exudative Ascites in the Course of Acute Type B Hepatitis. Hepatology, 2007, 3, 1013-1015. | 7.3 | 11 |
| 188 | Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology, 2007, 46, 1208-1217. | 7.3 | 166 |
| 189 | Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review. Gastroenterology, 2006, 131, 1611-1624. | 1.3 | 435 |
| 190 | Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. American Journal of Gastroenterology, 2006, 101, 506-512. | 0.4 | 228 |
| 191 | Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology, 2006, 43, 492-499. | 7.3 | 282 |
| 192 | Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. Seminars in Liver Disease, 2006, 26, 348-362. | 3.6 | 182 |
| 193 | Is treatment with nadolol effective against the growth of small esophageal varices in patients with cirrhosis?. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 18-19. | 1.7 | 6 |
| 194 | Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis. New England Journal of Medicine, 2005, 353, 2254-2261. | 27.0 | 952 |
| 195 | Treatment of variceal bleeding in patients with cirrhosis of the liver. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 111-119. | 0.1 | 0 |
| 196 | Variceal Bleeding: Pharmacological Therapy. Digestive Diseases, 2005, 23, 18-29. | 1.9 | 21 |
| 197 | Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. Journal of Hepatology, 2005, 43, 98-103. | 3.7 | 196 |
| 198 | Treatment of variceal bleeding in patients with cirrhosis of the liver. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 111-119. | 0.1 | 0 |

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology, 2004, 40, 1197-1202. | 7.3 | 142 |
| 200 | Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. Gastroenterology, 2004, 126, 469-475. | 1.3 | 468 |
| 201 | Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology, 2004, 126, 749-755. | 1.3 | 258 |
| 202 | Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology, 2004, 126, 886-894. | 1.3 | 236 |
| 203 | Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroenterology, 2004, 127, 1123-1130. | 1.3 | 386 |
| 204 | Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. Journal of Hepatology, 2004, 41, 384-390. | 3.7 | 141 |
| 205 | Management of gastrointestinal bleeding in patients with cirrhosis of the liver. Seminars in Hematology, 2004, 41, 8-12. | 3.4 | 22 |
| 206 | Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology, 2003, 37, 378-384. | 7.3 | 78 |
| 207 | Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology, 2003, 37, 902-908. | 7.3 | 456 |
| 208 | Current management of portal hypertension. Journal of Hepatology, 2003, 38, 54-68. | 3.7 | 245 |
| 209 | Prevention of variceal rebleeding. Lancet, The, 2003, 361, 952-954. | 13.7 | 398 |
| 210 | Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Gut, 2003, 52, 130-133. | 12.1 | 22 |
| 211 | A la carte or menu fixe: Improving pharmacologic therapy of portal hypertension. Hepatology, 2002, 36, 1330-1332. | 7.3 | 12 |
| 212 | Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373. | 7.3 | 121 |
| 213 | Reply:. Hepatology, 2002, 36, 260-260. | 7.3 | 1 |
| 214 | Neutrophil adhesion is impaired in the mesentery but not in the liver sinusoids of portal hypertensive rats. American Journal of Physiology - Renal Physiology, 2001, 280, G1351-G1359. | 3.4 | 4 |
| 215 | Effects of blood volume restitution following a portal hypertensive–related bleeding in anesthetized cirrhotic rats. Hepatology, 2001, 33, 821-825. | 7.3 | 125 |
| 216 | Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology, 2001, 34, 671-676. | 7.3 | 273 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology, 2000, 31, 581-586. | 7.3 | 77 |
| 218 | Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. Hepatology, 2000, 32, 471-476. | 7.3 | 196 |
| 219 | Prevention of Variceal Rebleeding: Endoscopes, Drugs, and More. Hepatology, 2000, 32, 660-662. | 7.3 | 11 |
| 220 | Gene structure of the mouse leukocyte cell surface molecule Ly9. Immunogenetics, 2000, 51, 788-793. | 2.4 | 19 |
| 221 | Pharmacological Treatment of Portal Hypertension: An Evidence-Based Approach. Seminars in Liver Disease, 1999, 19, 475-505. | 3.6 | 730 |
| 222 | Molecular cloning, characterization, and chromosomal localization of the mouse homologue of CD84, a member of the CD2 family of cell surface molecules. Immunogenetics, 1999, 49, 249-255. | 2.4 | 20 |
| 223 | Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha ₁ -adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology, 1999, 30, 79-83. | 7.3 | 158 |
| 224 | Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. Hepatology, 1999, 30, 445-453. | 7.3 | 21 |
| 225 | Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology, 1999, 117, 626-631. | 1.3 | 435 |
| 226 | Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology, 1998, 27, 351-356. | 7.3 | 64 |
| 227 | Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology, 1998, 28, 677-682. | 7.3 | 69 |
| 228 | Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. Gastroenterology, 1998, 114, 1296-1303. | 1.3 | 431 |
| 229 | Development of Analogues: Successes and Failures. Scandinavian Journal of Gastroenterology, 1998, 33, 3-13. | 1.5 | 27 |
| 230 | CD84 Leukocyte Antigen Is a New Member of the Ig Superfamily. Blood, 1997, 90, 2398-2405. | 1.4 | 76 |
| 231 | Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology, 1996, 111, 1018-1022. | 1.3 | 838 |
| 232 | Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 474-480. | 3.0 | 25 |
| 233 | Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology, 1995, 21, 83-88. | 7.3 | 35 |
| 234 | Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation. Hepatology, 1995, 22, 106-111. | 7.3 | 113 |

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 235 | The treatment of portal hypertension: A meta-analytic review. Hepatology, 1995, 22, 332-354. | 7.3 | 1,015 |
| 236 | Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology, 1995, 22, 753-758. | 7.3 | 90 |
| 237 | Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. Gastroenterology, 1995, 109, 1257-1265. | 1.3 | 130 |
| 238 | Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology, 1995, 108, 1487-1495. | 1.3 | 127 |
| 239 | Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet, The, 1995, 346, 1056-1059. | 13.7 | 569 |
| 240 | Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology, 1994, 19, 55-60. | 7.3 | 45 |
| 241 | Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology, 1994, 19, 1095-1099. | 7.3 | 111 |
| 242 | Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology, 1994, 19, 1257-1261. | 7.3 | 29 |
| 243 | Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology, 1994, 20, 30-33. | 7.3 | 55 |
| 244 | Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. Hepatology, 1994, 20, 336-341. | 7.3 | 52 |
| 245 | Gastric microcirculatory changes of Portal-hypertensive rats can be attenuated by long-term Estrogen-progestagen treatment. Hepatology, 1994, 20, 1261-1270. | 7.3 | 37 |
| 246 | Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects. Hepatology, 1994, 20, 1502-1508. | 7.3 | 67 |
| 247 | Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, september 19, 1992. Journal of Hepatology, 1994, 21, 461-467. | 3.7 | 116 |
| 248 | The treatment of major complications of cirrhosis. Alimentary Pharmacology and Therapeutics, 1994, 8, 639-657. | 3.7 | 14 |
| 249 | Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. Hepatology, 1994, 20, 336-341. | 7.3 | 4 |
| 250 | Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology, 1994, 19, 1257-1261. | 7.3 | 3 |
| 251 | Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Hepatology, 1993, 17, 213-218. | 7.3 | 41 |
| 252 | Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology, 1993, 17, 800-806. | 7.3 | 63 |

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. Hepatology, 1993, 18, 628-634. | 7.3 | 44 |
| 254 | Reduction of variceal pressure by propranolol: Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology, 1993, 18, 1082-1089. | 7.3 | 71 |
| 255 | Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. Hepatology, 1993, 18, 628-634. | 7.3 | 4 |
| 256 | Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology, 1992, 103, 1909-1915. | 1.3 | 252 |
| 257 | Definitions, methodology and therapeutic strategies in portal hypertension. Journal of Hepatology, 1992, 15, 256-261. | 3.7 | 273 |
| 258 | Long-term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: Importance of reversal of portal blood flow. Hepatology, 1992, 15, 616-622. | 7.3 | 24 |
| 259 | Pathophysiology of portal hypertension. Gastroenterology Clinics of North America, 1992, 21, 1-14. | 2.2 | 49 |
| 260 | Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet, The, 1991, 337, 1431-1434. | 13.7 | 264 |
| 261 | Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Hepatology, 1991, 13, 917-922. | 7.3 | 63 |
| 262 | Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Hepatology, 1991, 13, 917-922. | 7.3 | 1 |
| 263 | Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology, 1990, 99, 1401-1407. | 1.3 | 679 |
| 264 | Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology, 1990, 11, 230-238. | 7.3 | 172 |
| 265 | Effects of propranolol on gastric microcirculation and acid secretion in portal hypertensive rats. Hepatology, 1990, 12, 476-480. | 7.3 | 33 |
| 266 | Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting. Hepatology, 1989, 9, 808-814. | 7.3 | 99 |
| 267 | β-Blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology, 1989, 10, 269-272. | 7.3 | 22 |
| 268 | Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial. Hepatology, 1989, 10, 962-968. | 7.3 | 121 |
| 269 | Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Gastroenterology, 1989, 96, 1110-1118. | 1.3 | 153 |
| 270 | Evaluation of the portal hypertensive patient. Journal of Gastroenterology and Hepatology (Australia), 1989, 4 Suppl 1, 39-47. | 2.8 | 0 |

0

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology, 1988, 8, 636-642. | 7.3 | 170 |
| 272 | Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology, 1988, 8, 850-854. | 7.3 | 86 |
| 273 | Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. Hepatology, 1988, 8, 861-865. | 7.3 | 78 |
| 274 | Diagnosis and evaluation of portal hypertension. Zeitschrift Fur Gastroenterologie, 1988, 26 Suppl 2, 8-14. | 0.5 | 0 |
| 275 | Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: Comparison with measurements by variceal puncture in patients undergoing endoscopic sclerotherapy. Hepatology, 1986, 6, 667-672. | 7.3 | 110 |
| 276 | Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. Hepatology, 1986, 6, 1244-1247. | 7.3 | 38 |
| 277 | Efficacy of somatostatin and vasopressin in the control of acute variceal hemorrhage. Hepatology, 1985, 5, 344-345. | 7.3 | 15 |
| 278 | Measurement of Azygos Venous Blood Flow by a Continuous Thermal Dilution Technique: An Index of Blood Flow Through Gastroesophageal Collaterals in Cirrhosis. Hepatology, 1984, 4, 424-429. | 7.3 | 211 |
| 279 | Comparison of Intravenous Somatostatin and Vasopressin Infusions in Treatment of Acute Variceal Hemorrhage. Hepatology, 1984, 4, 442-446. | 7.3 | 243 |
| 280 | Correspondence. Is the Concept of "Exudative―Ascites Useful?. Hepatology, 1984, 4, 982-982. | 7.3 | 6 |
| 281 | Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin. Gastroenterology, 1981, 80, 518-525. | 1.3 | 342 |
| 282 | Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology, 1981, 80, 518-25. | 1.3 | 45 |
| 283 | Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. European Journal of Clinical Investigation, 1979, 9, 69-73. | 3.4 | 107 |
| 284 | Hepatopulmonary syndrome and portopulmonary hypertension. , 0, , 751-756. | | 0 |
| 285 | Adenocarcinoma (Gastric Cancer and Miscellaneous Malignancy). , 0, , 248-253. | | 0 |
| | | | |

286 Functional Gastrointestinal Disease. , 0, , 54-60.